Real world effectiveness of regorafenib in heavily pretreated patients with metastatic colorectal cancer.

被引：0
|
作者：
Danilova, Anastasia
Stroyakovsky, Daniil
Kanner, Dmitry
Chernikovksy, Ilya
Savelov, Nikita
Volkonsky, Mikhail
Demidova, Irina
机构：
[1] Moscow City Oncol Hosp 62, Krasnogorskiy Rayon, Russia
[2] Moscow City Oncol Hosp 62, Moscow, Russia
[3] Moscow City Oncol Hosp 62, Stepanovskoe, Russia
[4] SBIH Moscow City Oncol Hosp 62 DHM, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
298-11050; 283-237-255-11316; 261-492-199; 3282-206-4957-326-5009-5024-5025; 3282-206-4957-326-5009-2386; 613-135-244-3829-325; 10; 4; 3; 2; 250; 7; 38092-28187; 38092-25821; 38092-18849; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [21] Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer
    Larsen, Finn Ole
    Markussen, Alice
    Nielsen, Dorte
    Colville-Ebeling, Bonnie
    Riis, Lene B.
    Jensen, Benny V.
    ONCOLOGY, 2017, 93 (03) : 191 - 196
  • [22] Biweekly gemcitabine and capecitabine in heavily pretreated patients with metastatic colorectal cancer (mCRC)
    Solis Hernandez, Maria Del Pilar
    Jimenez, Paula
    Faez Garcia, Laura
    Alvarez Fernandez, Carlos
    Perez Arnillas, Quionia
    Rodriguez Rubi, David Jose
    Lucrecia Ruiz, Ana
    Sanchez Lorenzo, Luisa
    Li Torres, Walter Antonio
    Uriol, Esther
    Dolores, Maria
    Prieto, Menendez
    Maria Vieitez de Prado, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
    Liu, Xiu
    Ma, Xiaoting
    Ou, Kai
    Wang, Qi
    Gao, Lizhen
    Yang, Lin
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 277 - 289
  • [24] Efficacy and safety of immune checkpoint inhibitors in heavily pretreated patients with microsatellite stable metastatic colorectal cancer: a real-world retrospective study
    Zhao, Wensi
    Chen, Yongshun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (11): : 5378 - 5388
  • [25] Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
    Patel, Anuj K.
    Barghout, Victoria
    Yenikomshian, Mihran A.
    Germain, Guillaume
    Jacques, Philippe
    Laliberte, Francois
    Duh, Mei S.
    ONCOLOGIST, 2020, 25 (01): : E75 - E84
  • [26] Association of patient and disease characteristics with outcomes of regorafenib in patients with metastatic colorectal cancer.
    Hsieh, Ronan Wenhan
    Lee, Matthew
    Johnson, Devin
    Zhang, Chenxin
    Moon, Jee-Young
    Hsu, Dennis
    Acuna-Villaorduna, Ana
    Kuang, Chaoyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 135 - 135
  • [27] Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence
    Cervantes, Andres
    Tabernero, Josep
    Garcia-Carbonero, Rocio
    Sastre, Javier
    Feliu, Jaime
    Guillen-Ponceg, Carmen
    Paredes, Beatriz Garcia
    Carral, Alberto
    Munoz, Jorge
    FUTURE ONCOLOGY, 2024, 20 (20) : 1401 - 1413
  • [28] Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer
    Cosso, Federica
    Lavacchi, Daniele
    Fancelli, Sara
    Caliman, Enrico
    Brugia, Marco
    Rossi, Gemma
    Winchler, Costanza
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    ANTI-CANCER DRUGS, 2023, 34 (03) : 451 - 454
  • [29] Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life
    Sari, Murat
    Saip, Pinar
    INDIAN JOURNAL OF CANCER, 2020, 57 (01) : 55 - 61
  • [30] Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer
    Cheng, Ke
    Chen, Ye
    Li, Long-Hao
    Liu, Ji-Yan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (04) : 727 - 729
12345